FCER2 and allergic disease: Moreover, targeting CD23 with monoclonal antibody has been shown to decrease total serum IgE level in ~75% of allergic asthma patients in a phase I clinical trial and was proposed as candidate therapy for treating allergic diseases for some patient subgroups [131].